BRIEF—Shield broadens Swiss Feraccru label

Shield Therapeutics has broadened the Swiss label for Feraccru (ferric maltol) to include treatment of all adults with iron deficiency (ID), with or without anemia. The firm won European approval for this indication last year.

Chief executive Carl Sterritt said: “Switzerland represents an attractive market opportunity as it is both well reimbursed and has a much higher level of treatment penetration compared to other markets, particularly for IV iron therapies.”

“Together with the new label, we expect the recent positive result from the AEGIS-H2H Phase IIIb active comparator study of Feraccru versus intravenously delivered Ferinject will have added importance and will provide an enhanced commercial opportunity to Ewo, our Swiss commercial partner.”